Rumour has it that French drug giant Sanofi Aventis is planning to make a $20bn (€16bn) acquisition in the US with speculation that biotechs like Allergan, Biogen Idec and Genzyme are among the targets.
Sanofi Aventis has paid Unilife €10m for exclusive rights to use its Unifill ready-to-fill (RTF) syringe for the delivery of anti-thrombotic agents and vaccines.
Sanofi Pasteur has recalled four lots of its pediatric H1N1 vaccine in the US that were found to have fallen below potency limits despite being be in spec at the time of manufacture.
French drug major Sanofi Aventis has unveiled plans for a €200m ($268m) biotechnology investment at its manufacturing facility in Vitry-sur-Seine near Paris, under its collaborative Biolaunch project.
The Indian pharmaceutical and biotech sectors may see more M&A activity this year with rumours that GSK, Sanofi Aventis and Merck KGaA are on the look out for potential deals.